Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

They will try to silence us if they can and they are openly admitting to it in recent conferences and mainstream articles.

2 While very promising, Mylotarg’s toxicity profile and tight therapeutic window raised concerns, and it was withdrawn from the market in 2010 after a post-marketing trial highlighted real-world ...